Efficacy of immune checkpoint inhibitors according to programmed cell death‐ligand 1 expression in patients with non‐small cell lung cancer and brain metastasis: A real‐world prospective observational study

Efficacy of immune checkpoint inhibitors according to programmed cell death‐ligand 1 expression in patients with non‐small cell lung cancer and brain metastasis: A real‐world prospective observational study

Abstract Introduction Studies have shown the antitumor efficacy of immune checkpoint inhibitors (ICI) in patients with non‐small cell lung cancer (NSCLC) and brain metastases (BM). However, it is unclear whether the efficacy of ICI is similar between patients with and without BM. It is yet unclear w...

Full description

Bibliographic Details
Main Authors: Takeshi Masuda, Yukari Tsubata, Kojirou Hata, Mika Horie, Katsuyuki Kiura, Nobuhiro Kanaji, Takuya Inoue, Masahiro Kodani, Masaaki Yanai, Kakuhiro Yamaguchi, Naoko Matsumoto, Masahiro Yamasaki, Nobuhisa Ishikawa, Ken Masuda, Nagio Takigawa, Shoichi Kuyama, Tetsuya Kubota, Kazuya Nishii, Katsuyuki Hotta, Noboru Hattori
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Thoracic Cancer
Subjects:
brain metastasis
immune checkpoint inhibitor
non‐small cell lung cancer
programmed cell death‐ligand 1
Online Access:https://doi.org/10.1111/1759-7714.15469

Internet

https://doi.org/10.1111/1759-7714.15469

Similar Items